EFFICACY AND EFFECTIVENESS OF ALLOGENIC PLATELET LYSATE ON EQUINE JOINT TISSUE: IN VITRO, LABORATORY AND CLINICAL ASPECTS.

• Grant number: 24/20820-7
• Support Opportunities: Regular Research Grants
• Start date: July 01, 2025
• End date: June 30, 2027
• Field of knowledge: Agronomical Sciences - Veterinary Medicine - Animal Clinics and Surgery
• Principal Investigator: Raquel Yvonne Arantes Baccarin
• Grantee: Raquel Yvonne Arantes Baccarin
• Host Institution: Faculdade de Medicina Veterinária e Zootecnia (FMVZ). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Associated researchers: Cristina de Oliveira Massoco Salles Gomes ; Durvanei Augusto Maria ; Fernanda Rodrigues Agreste ; Julio David Spagnolo ; Luis Cláudio Lopes Correia da Silva ; Lynn Pezzanite ; Sarah Raphaela Torquato Seidel

Abstract

Orthobiologicals have been used with increasing frequency in veterinary medicine and are characterized as products of autologous or allogeneic origin, enriched in growth factors and with the potential to improve tissue repair capacity. Platelet Rich Plasma (PRP), which is widely used, has limitations in terms of storage, quality assessment before use in the joint environment and the possibility of triggering a transient inflammatory phase. In this scenario, there has been growing interest in the use of Platelet Lysate (PL) instead of fresh PRP, since PL is an acellular preparation containing high concentrations of growth factors and anti-inflammatory cytokines and can be considered the 2nd generation of PRP. The acellular nature of LP is important because it has the potential to be used allogeneically. In addition, LP allows its quality to be tested beforehand, can be stored frozen at -20°C and is available for immediate use in horses. The main disadvantage of using allogeneic LP is the lack of studies proving its efficacy or possible complications. This study aims to compare autologous PL with the allogeneic PL pool in terms of its anti-inflammatory and antimicrobial efficacy in in vitro systems; test safety on healthy joints, as well as its effectiveness as a therapy in animals naturally affected by joint disease. The methodology will be divided into two main studies: in vitro and in vivo, with characterization of the molecular content and inflammation markers in the orthobiologicals, culture media and synovial fluid; evaluation of cytotoxicity, immunogenicity and gene profile in the cells derived from the cultures; measurement of joint metabolism markers in the synovial fluid of healthy joints, and follow-up through clinical evaluations and imaging tests of the animals affected by joint diseases and submitted to the treatments. In conclusion, the aim is to offer a biological product of proven quality in the medium term, which can be stored and made readily available for application in the animal health area; also with a view to optimizing costs and resources, biosafety and facilitating the use of LP in veterinary practice. (AU)